[Federal Register Volume 75, Number 60 (Tuesday, March 30, 2010)]
[Notices]
[Pages 15711-15712]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-6966]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of Federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Zscan4, a Therapeutic Target for Cancer, Regenerative Medicine and
Aging
Description of Invention: This technology has broad potential for
the development of therapeutics for cancer, diseases of aging, and
regenerative medicine, and targets Zscan4, a gene that regulates
telomere length and genomic stability in embryonic stem (ES) cells.
The ability to maintain genomic stability in ES cells and other
stem cells is critical for the development of stem cell-based
therapies; genomic stability and telomere length are also active areas
of cancer and aging research. NIA investigators have discovered that
the Zscan4 gene regulates telomere length and genomic stability in ES
cells, and plays an essential role in early embryonic development; this
activity is independent of telomerase activity. The investigators have
shown that ablation of Zscan4 results in shortened telomere length and
deterioration of the karyotype of ES cells, and that Zscan4
overexpression increases telomere length.
This technology discloses methods for increasing genome stability
or increasing telomere length in an ES cell, and methods of treating a
subject in need of ES cell therapy. Also disclosed are methods of
promoting blastocyst outgrowth of embryonic stem cells, as well as
Zscan4 expression vectors and methods of identifying stem cells
expressing Zscan4.
Applications
Development of therapeutics for cancer treatment, aging,
and regenerative medicine.
Development of assisted reproduction technologies.
Studies of early embryonic development.
Development Status: In vitro and in vivo studies have been
performed.
Inventors: Minoru S. H. Ko et al. (NIA).
Publications
1. M Zalzman et al. Zscan4 regulates telomere elongation and
genomic stability in ES cells. Nature 2010 Mar 24; advance online
publication, doi 10.1038/nature08882.
2. G Falco et al. Zscan4: A novel gene expressed exclusively in
late 2-cell embryos and embryonic stem cells. Dev Biol. 2007 Jul
15;307(2):539-550. [PubMed: 17553482.]
Patent Status
HHS Reference No. E-088-2007/0--
PCT Application No. PCT/US2008/058261 filed 26 Mar 2008.
US Application No. 12/529,004 filed 27 Aug 2009.
Foreign counterparts in Europe, Australia, Canada, and
Japan
HHS Reference No. E-172-2009/0--
U.S. Provisional Application No. 61/275,983 filed 04 Sep
2009.
Licensing Status: Available for licensing.
Licensing Contact: Tara Kirby, PhD; 301-435-4426;
[email protected].
Collaborative Research Opportunity: The National Institute on
Aging, Laboratory of Genetics, is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. Please contact
Nicole Guyton, PhD at 301-435-
[[Page 15712]]
3101 or [email protected] for more information.
mFPR2 Transgenic and Knockout Mouse Models for Alzheimer's and Other
Inflammatory Diseases
Description of Invention: Human Formyl Peptide-Like Receptor 1
(hFPLR1) has been implicated in host defense for disease processes
including Alzheimer's disease, infection, and other inflammatory
diseases. hFPLR1 and its mouse homologue Formyl Peptide Receptor 2
(mFPR2) are G-protein coupled receptors that are expressed at high
levels on phagocytic leukocytes, mediating leukocyte chemotaxis and
activation in response to a number of pathogen- and host-derived
peptides. Activation of hFPRL1/mFPR2 by lipoxin A4 may play a role in
preventing and resolving inflammation. Also, hFPRL1/mFPR2 has been
shown to mediate the chemotactic activity of amyloid beta 1-42, a key
pathogenic peptide in Alzheimer's disease.
Available for licensing are mice expressing the mFPR2 transgene on
either the FVB or C58BL background, as well as mFPR2 knockout mice on
the C57BL background. These mice are anticipated to be highly useful in
the study of a wide variety of inflammatory, infectious, immunologic
and neurodegenerative diseases.
Applications
Drug development model for Alzheimer's disease and other
inflammatory diseases.
Tool to probe the role of hFPRL1/mFPR2 in host responses
in a variety of disease processes, including inflammatory, infectious,
immunologic, and neurodegenerative disease.
Inventors: Ji Ming Wang et al. (NCI)
Publications
1. K Chen, Y Le, Y Liu, W Gong, G Ying, J Huang, T Yoshimura, L
Tessarollo, JM Wang. Cutting Edge: A Critical Role for the G Protein-
Coupled Receptor mFPR2 in Airway Inflammation and Immune Responses. J
Immunol. 2010 Mar 3. Epub ahead of print. [PubMed: 20200280.]
2. K Chen, P Iribarren, J Hu, J Chen, W Gong, EH Cho, S Lockett, NM
Dunlop, and JM Wang. Activation of Toll-like receptor 2 on microglia
promotes cell uptake of Alzheimer disease-associated amyloid beta
peptide. J Biol Chem. 2006 Feb 10;281(6):3651-3659. [PubMed: 16339765.]
3. H Yazawa, ZX Yu, Takeda, Y Le, W Gong, VJ Ferrans, JJ Oppenheim,
CC Li, and JM Wang. Beta amyloid peptide (Abeta42) is internalized via
the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in
macrophages. FASEB J. 2001 Nov;15(13):2454-2462. [PubMed: 11689470.]
4. YH Cui, Y Le, W Gong, P Proost, J Van Damme, WJ Murphy, and JM
Wang. Bacterial lipopolysaccharide selectively up-regulates the
function of the chemotactic peptide receptor formyl peptide receptor 2
in murine microglial cells. J Immunol. 2002 Jan 1;168(1):434-442.
[PubMed: 11751990.]
Patent Status: HHS Reference No. E-303-2006/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: This technology is available as a research tool
under a Biological Materials License.
Licensing Contact: Tara Kirby, PhD; 301-435-4426;
[email protected].
Collaborative Research Opportunity: The National Cancer Institute--
Frederick, Laboratory of Molecular Immunoregulation, is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
mFPR2 Transgenic and Knockout Mouse Models for Alzheimer's and Other
Inflammatory Diseases. Please contact John D. Hewes, PhD at 301-435-
3121 or [email protected] for more information.
Dated: March 23, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-6966 Filed 3-29-10; 8:45 am]
BILLING CODE 4140-01-P